A new oral GLP-1 candidate posted trial data this month that’s worth reading past the headline number. Aleniglipron — a once-daily pill, not an injection — showed placebo-adjusted weight loss up to 11.3% in a phase 2b trial published in Nature Medicine and picked up widely this week. Here’s what the study actually found, and what a phase 2b trial doesn’t tell you yet.
What the ACCESS trial found
Aleniglipron is being developed by Structure Therapeutics. Unlike semaglutide and tirzepatide, which are peptides delivered by injection, it’s a small-molecule GLP-1 receptor agonist — meaning it’s chemically simpler and can be taken as a pill, without the food or water timing restrictions some earlier oral GLP-1 candidates required.
The ACCESS trial randomized 230 adults with obesity or overweight (average BMI 39.5, 54% women) to placebo or one of three doses — 45mg, 90mg, or 120mg — escalated over the first several weeks. It was randomized, double-blind, and placebo-controlled, which is the design that actually supports a causal claim about the drug, not just an association.
At week 36, placebo-adjusted weight loss was 8.2%, 9.8%, and 11.3% at the three doses (p<0.0001 versus placebo at every dose). An open-label extension — everyone knew they were on the drug at this point, and there was no placebo group to compare against — reported average weight loss up to 16.2% at 44 weeks.
Where the number gets softer
The 36-week, placebo-controlled result is the strongest evidence in this dataset. The 16.2% open-label number is not the same kind of evidence — without a placebo arm or blinding, it can’t rule out that people who stay in a trial longer are already the ones responding best, or that knowing you’re on active drug changes behavior. Treat it as a preview of a bigger study’s hypothesis, not a confirmed outcome.
A few other limits worth naming plainly:
- This is 36 weeks, not years. Nothing here speaks to what happens at 2 or 5 years, or what happens after stopping the drug.
- Discontinuation wasn’t trivial. 7.7% to 13.3% of participants across the active doses stopped due to adverse events — mostly gastrointestinal, mostly during the initial dose titration. A follow-on study (ACCESS II) is testing whether starting at a lower dose reduces that dropout, which is itself an admission that the tolerability profile in ACCESS wasn’t a solved problem.
- A trial average isn’t your number. 230 people with a specific average BMI, screened for trial eligibility, is not a representative sample of every adult who might take this drug. Individual results inside the trial varied considerably around that 11.3% average — the number describes the group, not any one participant in it.
- Phase 2b is not approval. This trial exists to justify a phase 3 program, the larger and longer study the FDA actually reviews for approval. Nothing about phase 2b data means aleniglipron is approved, available, or guaranteed to reach the market at all.
Why oral small molecules are a bigger story than one drug
Aleniglipron isn’t the only oral GLP-1 in this race. Orforglipron, sold as Foundayo, already cleared FDA approval earlier this year as the first oral small-molecule GLP-1 on the market — a useful reference point for what “approved” actually requires: a completed phase 3 program, an FDA review, and a label with specific dosing and warnings. That approval belongs to Lilly’s branded product alone; it says nothing about compounded medications, which are not FDA-approved and go through no such review. Aleniglipron hasn’t gotten there yet either.
The reason multiple companies are chasing an oral small molecule is manufacturing, not just convenience. Semaglutide and tirzepatide are peptides, which are harder and more expensive to manufacture at scale than a small-molecule pill — part of why injectable GLP-1s saw years of supply shortages. A pill that doesn’t require injection-device manufacturing or cold storage could, in principle, ease that bottleneck. That’s a manufacturing argument, not a clinical one, and it says nothing about whether aleniglipron specifically will work as well, cost less, or reach patients sooner than the injectables already on the market.
What this has to do with compounded medications
It’s worth being direct about what aleniglipron is not: it is not, and will never be, a compounded medication. Compounding exists for peptides like semaglutide and tirzepatide because licensed pharmacies can prepare them from bulk active ingredient for an individual patient’s prescription. Aleniglipron is a patented small molecule, still investigational, made by one company — there is no bulk-ingredient version a compounding pharmacy could prepare, and there won’t be one even after approval, the same way there’s no compounded orforglipron today.
That distinction matters because it’s easy to read a headline like “new pill beats the injections” and assume it says something about the compounded semaglutide and tirzepatide NoBsRx provides access to. It doesn’t. The trial evidence above belongs to a specific investigational branded product tested in a specific 230-person study. It doesn’t transfer to a compounded preparation, and compounded medications are not FDA-approved — that stays true regardless of what happens in the oral GLP-1 pipeline.
The takeaway
New GLP-1 data ships fast right now, and a lot of it gets flattened into “science says.” Phase 2b, placebo-controlled, 36-week data is real evidence. An open-label extension is a hint, not a result. And whatever happens to aleniglipron in phase 3 has no bearing on whether a compounded medication is right for you — that’s still a question for a licensed clinician who’s looked at your history, not a press release. If you’re weighing options, our provider-guided program starts with an actual clinical review, not an average from a trial you weren’t in.
This post is general information, not medical advice. It does not describe a benefit of any NoBsRx program, and aleniglipron is not a medication NoBsRx provides. Compounded medications are not FDA-approved. Treatment is never guaranteed — eligibility, diagnosis, and every treatment decision are made by independent licensed providers based on an individual clinical assessment, and availability varies by state. Do not start, stop, or change any treatment based on an article. Questions about whether a new or existing therapy is right for you belong with a licensed clinician.